Barclays PLC Has $15.86 Million Position in Enovis Co. (NYSE:ENOV)

Barclays PLC raised its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 16.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 368,488 shares of the company's stock after purchasing an additional 51,151 shares during the quarter. Barclays PLC owned 0.66% of Enovis worth $15,864,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. MML Investors Services LLC grew its stake in shares of Enovis by 17.2% in the 3rd quarter. MML Investors Services LLC now owns 44,179 shares of the company's stock valued at $1,902,000 after purchasing an additional 6,476 shares during the period. First National Bank of Omaha increased its position in Enovis by 3.0% in the 3rd quarter. First National Bank of Omaha now owns 53,866 shares of the company's stock valued at $2,319,000 after acquiring an additional 1,575 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Enovis during the third quarter worth approximately $217,000. Jane Street Group LLC increased its holdings in shares of Enovis by 247.6% in the third quarter. Jane Street Group LLC now owns 106,684 shares of the company's stock valued at $4,593,000 after purchasing an additional 75,988 shares in the last quarter. Finally, State Street Corp boosted its position in Enovis by 4.3% in the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company's stock valued at $70,913,000 after buying an additional 68,190 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target for the company. Finally, Evercore ISI cut their price objective on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Stock Down 0.8 %

Shares of ENOV traded down $0.36 on Monday, hitting $45.78. The company's stock had a trading volume of 440,909 shares, compared to its average volume of 580,056. The firm's fifty day moving average price is $44.38 and its 200-day moving average price is $44.56. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -20.90 and a beta of 1.94.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business's quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.56 earnings per share. On average, equities research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.